✦ LIBER ✦

On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study

✍ Scribed by Bas van den Bogaard; Bert-Jan H. van den Born; Rana Fayyad; David D. Waters; David A. DeMicco; John C. LaRosa; John J. P. Kastelein; Ingar Holme; On behalf of the Treating to New Targets investigators

Book ID: 108714055
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 168 KB
Volume: 41
Category: Article
ISSN: 0014-2972
DOI: 10.1111/j.1365-2362.2010.02387.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of intensive atorvast

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

✍ Douglas C. A. Taylor; Ankur Pandya; David Thompson; Paula Chu; Jennifer Graff; J 📂 Article 📅 2008 🏛 Springer 🌐 French ⚖ 293 KB

Cardiovascular outcomes and their relati

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

✍ I. Holme; R. Fayyad; O. Faergeman; J. J. P. Kastelein; A. G. Olsson; M. J. Tikka 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

Apolipoprotein B/A-I and total cholester

Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein

✍ P. J. W. H. Kappelle; R. T. Gansevoort; J. L. Hillege; B. H. R. Wolffenbuttel; R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB